T cell Lymphoma -Pipeline Insight, 2023

T cell Lymphoma -Pipeline Insight, 2023

DelveInsight’s, “T-cell Lymphoma -Pipeline Insight, 2023” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

T-cell lymphoma: Understanding

T-cell lymphoma: Overview

T-cell lymphomas are the uncommon and rare subtype of non-Hodgkin lymphomas that can develop in lymphoid tissues such as the lymph nodes and spleen, or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). This disease group has a poor prognosis compared to their B-cell counterpart. Most T-cell lymphomas develop from mature T cells. They usually affect adults, typically in people in their mid-60s. They are more common in men than in women. Occasionally, T-cell lymphoma can develop from immature T cells. This is known as T-cell lymphoblastic lymphoma. It tends to affect children and young adults. There are many types of T-cell lymphoma, including T-lymphoblastic lymphoma/leukemia, Peripheral T-cell lymphomas, Cutaneous T-cell lymphomas, Adult T-cell leukemia/lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, among others. With around 20 different types of T-cell lymphoma that can start in any area of your body, symptoms between people with T-cell lymphoma can differ greatly. Symptoms of T-cell lymphomas can vary depending on the particular type of lymphoma the patient have and where it develops in the body. The most common symptom of lymphoma is a swollen lymph node or nodes. Skin rashes or symptoms involving the skin are more common in some types of T cell lymphomas. Lymphoma that starts in the lymph nodes is called ‘nodal lymphoma’. However, many T-cell lymphomas develop outside the lymph nodes or in the organs – for example, in the liver, bone marrow, gut or skin. Some common symptoms of the lymphoma include fatigue, loss of appetite, pain in bone/ joints, muscle weakness, and liver enlargement. Since the T-cell lymphoma are rare, they are difficult to diagnose. The diagnosis usually involves biopsy, PET/CT scan. Also, some people, particularly children or people with lymphoma in the central nervous system, can have a MRI scan. The type of treatment needed for T-cell lymphoma will depend on the subtype of lymphoma, whether it is indolent or aggressive, symptoms and personal preferences. Some common treatment options include chemotherapy, monoclonal antibodies (Mabs) including cytokine inhibitors and conjugated Mabs, targeted therapies, and radiotherapy.

""T-cell Lymphoma -Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-cell Lymphoma pipeline landscape is provided which includes the disease overview and T-cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth T-cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence T-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve T-cell Lymphoma .

T-cell Lymphoma : Emerging Drugs Chapters

This segment of the T-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T-cell Lymphoma: Emerging Drugs

SGX 301: Soligenix

SGX301 (HyBryte™/ synthetic hypericin) is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. SGX301 is a photodynamic topical therapy using a hypericin ointment activated by visible light which is intended for patients managing early stage CTCL disease progression. HyBryte™ has been granted both Orphan Drug and Fast Track designation in the US, Orphan Drug designation in Europe and Promising Innovative Medicine designation by the UK Health Authority. The company has submitted a new drug application (NDA) to the US FDA)for HyBryte™ (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL).

Sugemalimab: CStone Pharmaceuticals

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which reduces the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs. In September 2022, the National Medical Products Administration (NMPA) of China has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).

IMC-001: ImmuneOncia Therapeutics

IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents. The drug is in Phase II for the treatment of NK/T-cell lymphoma.

Tolinapant: Astex Pharmaceuticals

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Tolinapant has a unique IAP antagonist molecular profile and has been shown to exert its activity through both IAP antagonism and via an immune-related mechanism. Currently, the drug is being evaluated in the Phase I/II (NCT05403450) for patients with peripheral T-cell lymphoma.

CPI-818: Corvus Pharmaceuticals

CPI-818 is an oral, small molecular drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase) and has the potential to provide a platform opportunity with broad applicability across lymphomas, solid tumors and autoimmune/allergic diseases. The optimal dose of CPI-818 has the potential to induce the activation, differentiation and expansion of T cells to TH1 helper cells while blocking the deployment of TH2 cells (TH1 skewing). Corvus and its partner in China, Angel Pharmaceuticals are conducting a Phase I trial in patients with refractory T-cell lymphomas that was designed to select the optimal dose of CPI-818 and evaluate its safety, pharmacokinetics, target occupancy, immunologic effects, biomarkers and efficacy.

Further product details are provided in the report……..

T-cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different T-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in T-cell Lymphoma

There are approx. 90+ key companies which are developing the therapies for T-cell Lymphoma . The companies which have their T-cell Lymphoma drug candidates in the most advanced stage, i.e. registered include, CStone Pharmaceuticals.

Phases

DelveInsight’s report covers around 90+ products under different phases of clinical development like

Late stage products (Registered)

Late stage products (Pre-registration)

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular

Intraocular

Intrathecal

Intravenous

Ophthalmic

Oral

Parenteral

Subcutaneous

Topical

Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide

Peptide

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T-cell Lymphoma : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T-cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-cell Lymphoma drugs.

T-cell Lymphoma : Report Insights

T-cell Lymphoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

T-cell Lymphoma : Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing T-cell Lymphoma drugs?

How many T-cell Lymphoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-cell Lymphoma ?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T-cell Lymphoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for T-cell Lymphoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Soligenix

CStone Pharmaceuticals

Genor Biopharma

Innate Pharma

ImmuneOncia Therapeutics

Astex Pharmaceuticals

Corvus Pharmaceuticals

ViGenCell Inc.

Affimed GmbH

MediSix Therapeutics

Dialectic Therapeutics

Artiva Biotherapeutics, Inc.

Key Products

SGX 301

Sugemalimab

Geptanolimab

Lacutamab

IMC-001

Tolinapant

CPI-818

VT-EBV-N

AFM-13

PCART3

DT2216

AB-101